619 West 54th Street, 8th Floor
23 articles about HiberCell
HiberCell to Present Pre-clinical Data on its Novel GCN2 Activator and PERK Inhibitor Programs at the American Association for Cancer Research (AACR) Annual Meeting 2023
HiberCell today announced three pre-clinical poster presentations which will be highlighted at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19 in Orlando, Florida.
HiberCell, a clinical-stage biotechnology company developing novel therapeutics to address mechanisms of metastasis, treatment resistance and cancer relapse, today announced data from a recent poster presentation at the American Association for Cancer Research (AACR) Special Conference: Acute Myeloid Leukemia and Myelodysplastic Syndrome, which took place from January 23-25, 2023 in Austin, Texas.
HiberCell to Present Preclinical Data from Novel GCN2 Activator and PERK Inhibitor Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, today announced two clinical abstract poster presentations at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting taking place November 8-12, 2022 in Boston, MA.
HiberCell to Present Posters on Novel Candidates Odetiglucan and HC-7366 at the 2022 Annual American Society of Clinical Oncology Meeting
HiberCell announced that it will present the background and design of two clinical trials of the Company’s therapeutic candidates, odetiglucan and HC-7366, in individual poster presentations at the 2022 Annual Meeting of the American Society of Clinical Oncology, which will be held in person and virtually on June 3-7, 2022 in Chicago, Illinois.
On Thursday, Mersana announced that the FDA granted an orphan drug designation to one of its lead assets, XMT-2056, which is intended to treat gastric cancer.
HiberCell Announces First Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® (pembrolizumab) in Adult Patients with Metastatic, Hormone-Refractory Breast Cancer
HiberCell today announced that the first patients have been dosed in a Phase 2 clinical trial of odetiglucan plus KEYTRUDA ® (pembrolizumab) for the treatment of metastatic, hormone-refractory breast cancer in adults.
The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week's clinical trial news.
HiberCell has initiated a Phase 1a/b clinical trial of HC-7366, a first-in-class selective, orally bioavailable modulator of General Control Nonderepressible 2 (GNC2) for the treatment of patients with advanced solid tumors.
12/20/2021It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look.
HiberCell to Collaborate with Merck on Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA® (pembrolizumab) in Patients with Metastatic Breast Cancer
HiberCell announced a clinical trial collaboration with Merck, known as MSD outside of the United States and Canada.
12/13/2021There were a lot of clinical trial announcements this week, driven by the European Society for Medical Oncology annual conference. Here’s a look.
HiberCell to Present Clinical Applications of Odetiglucan and the Role of Beta-Glucan in Cancer Treatment at ESMO Immuno-Oncology Virtual Congress 2021
HiberCell, a clinical-stage biotechnology company developing therapeutics to address therapeutic resistance, cancer relapse and metastasis, will deliver a virtual presentation on the clinical applications of our odetiglucan therapy for patients with metastatic and late-stage cancer at the ESMO Immuno-Oncology Virtual Congress 2021, December 8-11, 2021.
10/1/2021Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer relapse and metastasis, announced the appointment of Jonathan Lanfear as chief operating officer with a focus on leading and driving HiberCell’s emerging global reach.
HiberCell Receives Fast Track Designation from FDA for First-in-Human Studies of PERK Inhibitor (PERKi) HC-5404-FUHC-5404-FU PERKi Program is Currently in a Phase 1a Clinical Trial for the Treatment of Solid Tumors
HiberCell, a clinical stage biotechnology company developing therapeutics to treat cancer relapse and metastasis, announced that the U.S. Food and Drug Administration has granted the company Fast Track designation for HC-5404-FU, an orally administered PERK inhibitor for patients with solid tumors.
HiberCell announced today the acquisition of Genuity Science, Inc., a life science technology company that provides world-leading genomics and multi-omic analytics bolstered by an advanced artificial intelligence (AI) and machine learning (ML) platform to illuminate the underlying cause of cancer and other diseases.
7/2/2021Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
HiberCell Appoints Mark J. Mulvihill, Ph.D., Chief Scientific OfficerIndustry veteran promoted to oversee discovery of HiberCell’s scientific pipeline
HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, announced the appointment of Mark J. Mulvihill, Ph.D., as Chief Scientific Officer, who brings more than 20 years of experience in drug discovery and development with a focus on small molecule therapies.
5/26/2021Drug development requires solid funding. Here's who's standing on higher ground this week with fresh investment dollars.
12/4/2020Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.